PRLD vs RAPP
PRLD: An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms. RAPP: Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex neurological and psychiatric disorders.
Side-by-side fundamentals
| Metric | PRLD | RAPP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.92 | $41.33 | |
| Market cap as of 2026-07-23 | $313M | $2.1B | |
| PEG as of 2026-07-23 | n/a | -0.90 | |
| Net margin as of 2026-07-23 | -278.5% | n/a | |
| Operating margin as of 2026-07-23 | -310.7% | n/a | |
| ROE as of 2026-07-23 | -74.6% | -24.8% | RAPP higher |
| ROA as of 2026-07-23 | -39.3% | -23.4% | RAPP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +41.0% | n/a | |
| Beta as of 2026-07-23 | 0.94 | 2.58 | |
| 1-year return as of 2026-07-22 close | +379.8% | +195.8% | PRLD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.